Literature DB >> 21507846

Current and future treatment considerations in the management of aneurysmal subarachnoid hemorrhage.

Denise H Rhoney1, Karen McAllen, Xi Liu-DeRyke.   

Abstract

Aneurysmal subarachnoid hemorrhage (aSAH) is a type of hemorrhagic stroke that can cause significant morbidity and mortality. Although guidelines have been published to help direct the care of these patients, there is insufficient quality literature regarding the medical and pharmacological management of patients with aSAH. Treatment is divided into 3 categories: supportive therapy, prevention of complications, and treatment of complications. There are numerous pharmacological therapies that are targeted at prevention and treatment of the neurological and medical complications that may arise. Rebleeding, hydrocephalus, cerebral vasospasm, and seizures are the most common neurological complications while the most common medical complications include hyponatremia, pulmonary edema, cardiac arrhythmias, neurogenic stunned myocardium, fever, anemia, infection, hyperglycemia, and venous thromboembolism. Risk factors, clinical presentation, diagnosis, pathophysiology, as well as initial management, prevention, and treatment of complications will be the focus of this discussion.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21507846     DOI: 10.1177/0897190010372334

Source DB:  PubMed          Journal:  J Pharm Pract        ISSN: 0897-1900


  2 in total

1.  Incidence of and factors associated with manipulation of nimodipine dosage in patients with aneurysmal subarachnoid hemorrhage.

Authors:  Meghan MacKenzie; Sean K Gorman; Steve Doucette; Robert Green
Journal:  Can J Hosp Pharm       Date:  2014-09

2.  Milrinone and homeostasis to treat cerebral vasospasm associated with subarachnoid hemorrhage: the Montreal Neurological Hospital protocol.

Authors:  Marcelo Lannes; Jeanne Teitelbaum; Maria del Pilar Cortés; Mauro Cardoso; Mark Angle
Journal:  Neurocrit Care       Date:  2012-06       Impact factor: 3.210

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.